Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-18.6
Face value
--
Shares outstanding
1,394,671
CFO
$-185.35 Mln
EBITDA
$-203.68 Mln
Net Profit
$365.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neximmune Inc (NEXI)
| -- | -- | -- | -- | -97.8 | -95.5 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Neximmune Inc (NEXI)
| -63.5 | -94.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neximmune Inc (NEXI)
|
0.0 | 0.0 | 2.1 | -20.6 | -630.9 | -930.7 | -- | 0.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell... immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Read more
CEO, President & Director
Ms. Kristi Jones R.Ph.
CEO, President & Director
Ms. Kristi Jones R.Ph.
Headquarters
Gaithersburg, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neximmune Inc (NEXI) is $0.00 (NASDAQ) as of 02-Apr-2026 09:30 EDT. Neximmune Inc (NEXI) has given a return of -97.81% in the last 3 years.
Since, TTM earnings of Neximmune Inc (NEXI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.07
|
0.67
|
|
2022
|
0.00
|
0.01
|
|
2021
|
-0.08
|
0.05
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Neximmune Inc (NEXI) are Rs 0.00 and Rs 0.00 as of 05-Apr-2026.
Neximmune Inc (NEXI) has a market capitalisation of $ 0 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Neximmune Inc (NEXI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.21
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.